Protein / target
Tyrosinase
Protein at a glance
Biological role
Protein homodimerization
Strongest disease association
Vitiligo
Therapeutic position
Established drug target
Research activity
Emerging research
Derived from structured UniProt, Open Targets and literature data on this page.
Protein profile
Canonical identity and biological annotation from UniProt.
Function overview
This is a copper-containing oxidase that functions in the formation of pigments such as melanins and other polyphenolic compounds.
View complete UniProt function annotationHide complete annotation
This is a copper-containing oxidase that functions in the formation of pigments such as melanins and other polyphenolic compounds. Catalyzes the initial and rate limiting step in the cascade of reactions leading to melanin production from tyrosine (By similarity). In addition to hydroxylating tyrosine to DOPA (3,4-dihydroxyphenylalanine), also catalyzes the oxidation of DOPA to DOPA-quinone, and possibly the oxidation of DHI (5,6-dihydroxyindole) to indole-5,6 quinone (PubMed:28661582)
Subcellular location
Domains and Gene Ontology detail (19)Hide
Gene Ontology
- Ccytoplasm
- CGolgi-associated vesicle
- Clysosome
- Cmelanosome
- Cmelanosome membrane
- Cperinuclear region of cytoplasm
- Fcopper ion binding
- Fidentical protein binding
- Fprotein homodimerization activity
- Ftyrosinase activity
- Peye pigment biosynthetic process
- Pmelanin biosynthetic process
Translational evidence
Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.
Strongest disease associations · via encoding gene TYR
Gene-level evidence surfaced through the gene TYRthat encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.
View evidence synthesis (2)Hide
The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.
Show all associationsHide all associations
Drug development
2 compounds recorded · 1 approved · 1 in clinical development
View all recorded compounds (2)Hide
Open Targets known-drugs universe. Drug name and highest clinical stage only — the disease relationship is NOT read from this slice (it carries trial-context noise); approved indications come from the canonical graph above.
Tractability
Small molecules — Strong
Antibodies — Emerging
Protein degraders — Emerging
View underlying tractability evidence (5)Hide
Raw Open Targets tractability assessment buckets, by modality.
Research activity
Papers linked directly to this protein. This is the protein's own literature — descriptor-derived papers are kept separate below.
Most cited
Recent
Europe PMC papers linked directly to this protein.